AbbVie Q3 Revenue Rises 10.3% to $17.4 Billion; Adjusted EPS Reaches $3.82

{
  "signal_id": "3a6a069f-9b0b-ad83-e060-035372fb8b06",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-10-30T11:53:00+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "url": "https://www.tradingview.com/news/tradingview:56bb8f99e7994:0-abbvie-q3-revenue-rises-10-3-to-17-4-billion-adjusted-eps-reaches-3-82/",
    "title": "AbbVie Q3 Revenue Rises 10.3% to $17.4 Billion; Adjusted EPS Reaches $3.82 - TradingView",
    "excerpt": "AbbVie reported third-quarter 2026 revenue of $17.404 billion, up 10.3% year over year, and GAAP diluted EPS of $2.37. Adjusted diluted EPS was $3.82, including an unfavorable $0.11-per-share impact from acquired IPR&D and milestone expense. The company raised its full-year adjusted EPS guidance and announced a 5.2% dividend increase. Financial Highlights Business Highlights Original SEC Filing: AbbVie Inc. [ ABBV ] - 8-K - Oct. 30, 2026",
    "summary": "AbbVie reported third-quarter 2026 revenue of $17.404 billion, an increase of 10.3% year over year.",
    "planning": false,
    "image_url": "https://s.tradingview.com/static/images/illustrations/news-story.jpg",
    "confidence": 0.95,
    "published_at": "2026-10-30T11:53:00Z",
    "effective_date": "2026-10-30",
    "article_sentence": "AbbVie reported third-quarter 2026 revenue of $17.404 billion, up 10.3% year over year, and GAAP diluted EPS of $2.37.",
    "amount_normalized": 17404000000
  }
}

curl https://signals.autobound.ai/v1/signals/3a6a069f-9b0b-ad83-e060-035372fb8b06 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'